title: Effect of alaptide, its analogues and oxiracetam on memory for an elevated plus-maze in mice.
abstract: In the present study, the elevated plus-maze was used to evaluate memory in female mice. In Experiment 1, the mice retested on day 1, 4 or 7 after the initial session escaped from the open arm into the enclosed arm in a significantly shorter time than those retested on day 10 or 14. Thus, a 10-day inter-session interval was chosen for testing drugs which were expected to enhance memory. In Experiment 2, in the retest performed on day 10, both alaptide (cyclo(L-alanyl-1-amino-1- cyclopentanecarbonyl)) and oxiracetam, given immediately after the 1st session, reduced the transfer latency from the open arm into the enclosed arm as compared with that of the controls. In Experiment 3, a similar effect, i.e., the retention of spatial information, was facilitated by post-session injections of 5 out of 21 alaptide analogues. The new compounds represent the 2,5-piperazinedione derivatives which contain 1-amino-1-cyclo-alkanecarboxylic acid (C3 to C7 ring). The cyclopentane- and cyclohexane-ring was substituted by an alkyl group. In the series with the cycloalkane ring, the importance of the structure of alaptide was confirmed again, which underlines the importance of the cyclopentane ring; the active structures had L-alanine instead of glycine as the second amino acid. Isomers of the cyclohexane series which contained methyl or tert-butyl were most active when the substitution was at position 3. Our results demonstrate that the model of long-term memory can be used to discriminate between closely related chemical structures.
authors.affiliation: Research Institute for Pharmacy and Biochemistry, Prague, Czech Republic.
authors.forename: Z
authors.initials: Z
authors.lastname: Hlinák
authors.forename: J
authors.initials: J
authors.lastname: Vinsová
authors.forename: E
authors.initials: E
authors.lastname: Kasafírek
mesh_terms: D000818:Animals; D005260:Female; D018782:Maze Learning / Q000187:drug effects*; D008568:Memory / Q000187:drug effects*; D051379:Mice; D009479:Neuropeptides / Q000494:pharmacology*; D010456:Peptides, Cyclic / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D009479:Neuropeptides; D010456:Peptides, Cyclic; D010879:Piperazines; D011619:Psychotropic Drugs; D011759:Pyrrolidines; C049178:cyclo(alanine-(1-amino-1-cyclopentane)carbonyl); C040619:oxiracetam